A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

NCT ID: NCT03437590

Last Updated: 2025-04-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-03-15
• Study Completion Date: 2018-10-19

Brief Summary

The purpose of this study is to measure the blocking of [18F]-JNJ-64413739 uptake in the brain at the time to reach maximum plasma concentration (Tmax) and at 24 hours postdose of JNJ-55308942 following a single dose of JNJ-55308942; and to model the exposure/receptor interaction of JNJ-55308942.

Conditions

Healthy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Part 1: JNJ-55308942 and [18F]-JNJ-64413739

Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with \[18F\]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram \[mg\]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of \[18F\]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.

Group Type: EXPERIMENTAL

JNJ-55308942

Intervention Type: DRUG

JNJ-55308942 will be administered as oral solution.

[18F]-JNJ-64413739

Intervention Type: DRUG

\[18F\]-JNJ-64413739 fluid for injection administered intravenously.

Part 2: JNJ-55308942 and [18F]-JNJ-64413739

Participants will first undergo a baseline PET/MR scan with \[18F\]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.

Group Type: EXPERIMENTAL

JNJ-55308942

Intervention Type: DRUG

JNJ-55308942 will be administered as oral solution.

[18F]-JNJ-64413739

Intervention Type: DRUG

\[18F\]-JNJ-64413739 fluid for injection administered intravenously.

Interventions

JNJ-55308942

JNJ-55308942 will be administered as oral solution.

Intervention Type: DRUG

[18F]-JNJ-64413739

\[18F\]-JNJ-64413739 fluid for injection administered intravenously.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) between 18 and 30 kilogram per meter square (kg/m^2) inclusive (BMI = weight/height^2)
• Is willing to allow the investigators to place an arterial catheter in the radial artery, is assessed via physical examination (Allen Test) to be a good candidate for arterial catheter placement and should not be allergic to local anesthetics for catheter placement
• During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug participants must agree not to donate sperm. If a participant is sexually active with a woman he should agree to the following: (a) If it concerns a woman of childbearing potential and the participant has not had a vasectomy, the participant must agree to use a condom and make sure his female partner is using a highly effective method of birth control during the study and for a minimum of 90 days after the last dose of study drug. (b) If it concerns a woman of nonchild bearing potential, who is pregnant or has been sterilized and the participant has not had a vasectomy, the participant must agree to use a condom for the given period. (c) If the participant has had a vasectomy, he should agree to use a condom when being sexually active with a woman of child bearing potential. Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants participating in clinical studies
• Participants must have signed an informed consent document indicating that they understand the purpose of, and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions

Exclusion Criteria

• Exposed to greater than (>) 1 millisievert (mSv) of ionizing radiation participating as a participant in research studies in the 12 months before the start of this study
• Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the Principal Investigator, are acceptable
• Clinically significant abnormal physical and neurological examination, vital signs or 12-lead electrocardiogram (ECG) at screening or admission
• History of or current significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, coagulation abnormalities, or other conditions that the Investigator considers should exclude the participant and preclude their ability to participate in study procedures. Participants with a history significant liver or renal disease, or difficulty in urination, which could affect the metabolism and elimination of the radiotracer or radiometabolites should be excluded. Participants with a history of epilepsy or fits or unexplained black-outs or loss of consciousness should also be excluded
• Participant has a QT corrected according to Fridericia's formula (QTcF) interval of >450 millisecond (msec) at Screening or prior to "baseline" on Day 1, or has a history of additional risk factors for torsades de pointes (example, heart failure, hypokalemia, family history of Long QT Syndrome)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen-Cilag International NV

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen-Cilag International NV Clinical Trial

Role: STUDY_DIRECTOR

Janssen-Cilag International NV

Locations

UZ Leuven Gasthuisberg

Leuven, , Belgium

Countries

Belgium

Other Identifiers

2017-004517-55

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

55308942EDI1002

Identifier Type: OTHER

Identifier Source: secondary_id

CR108439

Identifier Type: -

Identifier Source: org_study_id